Stockscreener 앱 받기
114.33
0.16%
-0.18
시간 외 거래:
114.30
-0.03
-0.03%
전일 마감가:
$114.51
열려 있는:
$114.55
하루 거래량:
1.44M
Relative Volume:
0.70
시가총액:
$6.69B
수익:
$22.29M
순이익/손실:
$-228.93M
주가수익비율:
-28.20
EPS:
-4.0547
순현금흐름:
$-212.59M
1주 성능:
+0.03%
1개월 성능:
+71.85%
6개월 성능:
+46.84%
1년 성능:
+60.24%
1일 변동 폭
$114.30
$114.74
1주일 범위
$114.30
$114.77
52주 변동 폭
$47.86
$114.80
Arcellx Inc Stock (ACLX) Company Profile
명칭
Arcellx Inc
전화
240-327-0603
주소
800 BRIDGE PARKWAY, REDWOOD CITY
Compare ACLX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACLX
Arcellx Inc
|
114.33 | 6.70B | 22.29M | -228.93M | -212.59M | -4.0547 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcellx Inc Stock (ACLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-12 | 다운그레이드 | Rothschild & Co Redburn | Buy → Neutral |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-22 | 개시 | Wells Fargo | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-16 | 개시 | Stifel | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2024-10-08 | 개시 | Redburn Atlantic | Buy |
| 2024-09-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-03-07 | 개시 | Morgan Stanley | Overweight |
| 2024-01-04 | 재확인 | Needham | Buy |
| 2023-12-19 | 개시 | Scotiabank | Sector Outperform |
| 2023-10-30 | 개시 | TD Cowen | Outperform |
| 2023-10-17 | 개시 | UBS | Buy |
| 2023-05-18 | 개시 | Truist | Buy |
| 2023-04-14 | 개시 | Robert W. Baird | Outperform |
| 2023-03-14 | 개시 | Stifel | Buy |
| 2023-02-13 | 개시 | H.C. Wainwright | Buy |
| 2022-12-13 | 재개 | BofA Securities | Buy |
| 2022-10-31 | 개시 | Guggenheim | Buy |
| 2022-10-27 | 개시 | Needham | Buy |
| 2022-07-20 | 개시 | Canaccord Genuity | Buy |
| 2022-03-01 | 개시 | BofA Securities | Buy |
| 2022-03-01 | 개시 | SVB Leerink | Outperform |
모두보기
Arcellx Inc 주식(ACLX)의 최신 뉴스
Arcellx (ACLX) CFO gifts 5,000 shares to family foundation - Stock Titan
Are ACLX, MASI, FONR Obtaining Fair Deals for their Shareholders? (2026-03-19) - Seeking Alpha
JPMorgan Chase & Co. Decreases Holdings in Arcellx, Inc. $ACLX - MarketBeat
Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Benzinga
Gilead buys Arcellx to fast-track next-gen myeloma drug - MSN
Arcellx, Inc.Common Stock (NQ: ACLX - The Chronicle-Journal
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - AOL.com
Institution Moves: Is Arcellx Inc stock a smart retirement pickWeekly Trade Analysis & Risk Managed Investment Signals - baoquankhu1.vn
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth - MarketBeat
Arcellx and Aardvark Therapeutics Compared - National Today
(ACLX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
Are MASI, ACLX, GLDD Obtaining Fair Deals for their Shareholders? (2026-03-16) - Seeking Alpha
Arcellx, Inc. $ACLX Position Lifted by HighVista Strategies LLC - MarketBeat
Bamco Inc. NY Increases Stake in Arcellx, Inc. - National Today
Bamco Inc. NY Has $45.17 Million Stake in Arcellx, Inc. $ACLX - MarketBeat
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Arcellx set to report earnings amid $7.8B Gilead deal By Investing.com - Investing.com Nigeria
Integral Health Asset Management LLC Invests $12.32 Million in Arcellx, Inc. $ACLX - MarketBeat
Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arcellx, Inc.ACLX - FinancialContent
Gilead Sciences to buy Arcellx in deal worth up to $7.8B - MSN
Shareholder Alert: The Ademi Firm Investigates Whether Arcellx Inc. Is Obtaining a Fair Price for Its Public Shareholders - 富途牛牛
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? - sharewise.com
Short Interest in Arcellx, Inc. (NASDAQ:ACLX) Declines By 38.0% - MarketBeat
Arcellx shares surge after Gilead announces $7.8B takeover deal - MSN
Victory Capital Management Inc. Has $14.13 Million Stock Position in Arcellx, Inc. $ACLX - MarketBeat
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification - simplywall.st
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Insider Monkey
Are ACLX, DBRG, AVO, CVGW Obtaining Fair Deals for their Shareholders? - Sahm
Arcellx set to report earnings amid $7.8B Gilead deal - Investing.com
American Century Companies Inc. Has $33.82 Million Position in Arcellx, Inc. $ACLX - MarketBeat
Gilead to buy US biotech Arcellx for up to $7.8 billion - MSN
Blue Owl Capital Holdings LP Buys Shares of 26,823 Arcellx, Inc. $ACLX - MarketBeat
Arcellx (NASDAQ: ACLX) backs $115 cash plus $5 CVR tied to $6B anito-cel sales - Stock Titan
(ACLX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arcellx Inc share price - Capital.com
Gilead Sciences stock forecast for 2030: Can $7.8B Arcellx deal push GILD to $220 with no patent cliff until 2036? - Traders Union
Arcellx, Inc. (NASDAQ:ACLX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Halper Sadeh LLC is Investigating Whether ACLX, VRE, EHAB are Obtaining Fair Deals for their Shareholders - GlobeNewswire
Top 2 Health Care Stocks That May Crash This QuarterArcellx (NASDAQ:ACLX), Anika Therapeutics (NASDAQ:ANIK) - Benzinga
Multiple Myeloma Market 2026: Gilead Sciences Acquires Arcellx for $7.8B to Control CAR-T Therapy - openPR.com
Arcellx (ACLX) director gifts 101,164 shares to family foundation - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Alkermes (ALKS) and Progyny (PGNY) - The Globe and Mail
Arcellx Inc stock hits all-time high at 114.27 USD - Investing.com Australia
Are ACLX, VRE, LSF Obtaining Fair Deals for their Shareholders? - Stock Titan
Gilead Sciences’ Yeztugo Revenue Is Set to Jump 400%: Here’s What Comes Next - TIKR.com
Arcellx (NASDAQ:ACLX) Hits New 52-Week HighStill a Buy? - MarketBeat
Arcellx Inc stock hits all-time high at 114.27 USD By Investing.com - Investing.com UK
Arcellx, Inc. (ACLX) Stock Analysis: Navigating Biotech’s Cutting Edge with Strategic Alliances - DirectorsTalk Interviews
Cowen Downgrades Arcellx, Inc. (ACLX) to Hold on March 2, 2026 - Meyka
ACLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Arcellx Inc (ACLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):